Town of Bel Air Awards Settlement Contract to Alvogen Inc. (September 2025)
- Approved
- Sep 15, 2025
The 30-second brief
The Board of Town Commissioners approved the Resolution No. 1258-25 authorizing the town administrator, special counsel, and staff to execute and deliver opioid litigation settlements with seven opioid manufacturers: Alvogen, Amneal, Apotex, Hikma, Mylan, Sun, and Zydus. Maryland's estimated potential share for the settlements is approximately $12 million.
Alvogen Inc. holds this settlement contract with Town of Bel Air. Its other public contracts on record include work for Carter County and Julesburg Housing Authority.
See every contract and contact at Town of Bel Air.
See every contractFree account · 30-second setup · No credit card
Contract details
- Contract type
- Settlement
- Document date
- September 15, 2025
- Term
- NA
- Vendor
- Alvogen Inc.
- Agency
- Town of Bel Air
- Source document
- bel-air-board-of-commissioners-town-hall-meeting-minutes-september-15-2025_96b.pdf (Minutes)
Alvogen Inc.'s other public contracts
More Town of Bel Air contracts
Questions about this contract
Who was awarded the settlement contract by Town of Bel Air?
Alvogen Inc. was awarded this settlement contract by Town of Bel Air, as recorded on September 15, 2025.
What type of contract is this?
This is a Settlement contract, documented as a minutes record.
Where was this contract approved?
This contract appears in bel-air-board-of-commissioners-town-hall-meeting-minutes-september-15-2025_96b.pdf (Minutes), dated September 15, 2025 from Town of Bel Air. Civic IQ extracts contract records directly from agency meeting documents and solicitations.
What other contracts does Alvogen Inc. hold?
Alvogen Inc. may hold additional government contracts. View their full contract history, the agencies they serve, and total tracked spend on their Civic IQ vendor profile.
Show 1 more question
What is Town of Bel Air currently buying?
Explore Town of Bel Air's vendors, signed contracts, and active RFPs on their Civic IQ agency profile.